LLY | tickerfilter.com

Fundamental analysis

81%

Profitability 100%

Dept financing 33%

Liquidity 57%

Performance 80%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.07%

1 Month

-4.97%

3 Months

5.27%

6 Months

-9.40%

1 Year

8.33%

2 Year

149.18%

Key data

Stock price

$837.57

P/E Ratio

65.79

DAY RANGE

$825.32 - $850.42

EPS

$11.76

52 WEEK RANGE

$711.40 - $972.53

52 WEEK CHANGE

$8.33

MARKET CAP

696.733 B

YIELD

0.67%

SHARES OUTSTANDING

950.426 M

DIVIDEND

$1.50

EX-DIVIDEND DATE

02-14-2025

NEXT EARNINGS DATE

N/A

BETA

0.81

PUBLIC FLOAT

AVERAGE 10 VOLUME

$3,693,509

AVERAGE 30 VOLUME

$3,767,157

Company detail

CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

LLY - ELI LILLY & Co